Industrial Technology Research Institute

Other

Taipei Medical University

Yung Shin Pharm. Ind. Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

Syn-tech Chem. & Pharm. Co., Ltd.

Angiorx Corporation

On Lee

Hui-po Wang

Che-Ming Teng

Chrong-Shiong Hwang

Chih-Hung Chen

Jih-Hwa Guh

Chin-Tsai Fan

Ting-Shou Chen

Jenn-Tsang Hwang

Yuan-Jang Tsai

Chi-Y Hung

Ya-Bing Fan

Huei-Ting Chen

Eric I C Li

Ya-Lan Chen

Mei-Hsuan Tsai

Sheng-Chu Kuo

Hsin-Hsin Shen

Yu-Wen Cheng

Fang-Yu Lee

Lain-Tze Lee

Mao-Yuan Lin

Ping-Fu Cheng

Chuan-Ching Yang

Chih-Peng Liu

Ying-Chu Shih

Yen-Chun Chen

Chen-Yi Su

Tsan-Lin Hu

Tsang-Miao Huang

Maggie Lu

Shun-Chi Wu

Chi-Chiang Tu

Yi-Ju Ko

Chun-Min Liu

Ching-Huai Ko

Chi-Ying Hung

Yow-Lone Chang

Chun-Li Wang

Jin-Yuh Shew

Ling-Mei Wang

Kuei-Tai Lai

Nanshan Zhong

Feng-Shuo Chang

Shui-Jane Lee

Hui-Po Wang

Chin-Yi Wu

Jheng-Sian Li

Chiu Hsing Lin

Shing Mein Wu

Hsiao Che-Chih

Lain-tze Lee

Che-Chih Hsiao

A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided. 

Compounds, linker-drugs and ligand-drug conjugates

An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.A-(L-D)&#x2003;&#x2003;(I)

Antibody-drug conjugate (ADC) and method for forming the same

Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.

Benzenesulfonamide derivatives and method for treating cancer

An azaazulene compound is provided. The azaazulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. The compound can be used to treat cancer. The invention also provides a method for treating cancer. The method includes administering to a subject in need thereof an effective amount of one or more azaazulene compounds of formula (I).

Azaazulene compounds

This invention relates to compounds of the following general formula: The variables are defined herein. Also disclosed is a method for treating mucositis or cancer using these compounds.

Histone deacetylase inhibitors

A huperzine A compound is provided. The huperzine A compound has following formula: 

Huperzine a compound for treatment of alzheimer's disease

The invention is related to novel azulene-oxindole compounds having formula (I) shown below, wherein one of R, Rand Rrepresents a moiety of formula (II), each of Aand Aindependently is nitrogen, oxygen or sulfur, each of the others of R, R, R, R, R, R, R, R, R, R, R, R, R, and Ris as recited in the specification. The novel compound potentially inhibits multiple kinases and thus can be used to treat some disease like cancer or inflammatory. 

Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents

An oligopeptide comprises formulae (I) or (II)  the oligopeptide derivative thereof, and a pharmaceutical composition comprising the same are provided.

NAP derivatives

This invention relates to a method for treating an angiogenesis-related disease. The method includes administering to a subject in need thereof an effective amount of a piperazinedione compound having the formula: In the above formula, each ofand, independently, is a single bond or a double bond; A is H or CH(RR) whenis a single bond, or C(RR) whenis a double bond; Z is CH(RR) whenis a single bond, or C(RR) whenis a double bond; each of Rand R, independently, is H, C(O)R, C(O)OR, C(O)NRR, or SOR; and each of R, R, R, R, R, and R, independently, is H, C-Calkyl, aryl, heteroaryl, C-Ccycloalkyl, or C-Cheterocycloalkyl; or Rand Rtaken together are C-Ccycloalkyl, C-Cheterocycloalkyl, aryl, or heteroaryl; or Rand Ror Rand Rtaken together are C-Ccycloalkyl, C-Cheterocycloalkyl, aryl, or heteroaryl; provided that one of Rand Ris aryl or heteroaryl.

Piperazinedione compounds

The present invention synthesizes a series of novel indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2&#x2032;-furyl)indazole (YC-1), and their anti-platelet activity.

Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2&#x2032;-furyl) indazole (YC-1) as anti-platelet agents

A novel anti-oncogenic azatyrosine analogues of formula (I) ##STR1## wherein R.sub.1 is C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, benzyl, or (C.sub.1-6 alkyl)carbonyl; R.sub.2 is C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, or C.sub.1-6 alkoxyl; and R.sub.3 is CONR.sub.4 R.sub.5, CONHNR.sub.4 R.sub.5, or COOR.sub.6, wherein each R.sub.4 and R.sub.5 independently is a hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, or C.sub.3-6 cycloalkyl, or R.sub.4 and R.sub.5 taken together with the nitrogen attached thereto form a C.sub.3-8 heterocyclic group; R.sub.6 is C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, or benzyl. Also disclosed is a method of preparing such a novel anti-oncogenic azatyrosine analogues, as well as a pharmaceutical composition containing a compound of formula (I).

Azatyrosine analogues

Novel anticholesteremic compounds capable of reducing blood cholesterol levels. Also included in this invention are (i) intermediates from which the abovementioned anticholesteremic compounds can be prepared, and (ii) methods for preparing both the intermediates and the anticholesteremic compounds.

Anticholesteremic compounds

Novel 3-substituted derivatives of 2,2-dimethyl-5-substituted phenoxy-pentanoic acids of formula (I) are prepared. These compouds are prepared from 2,2-dimethyl-5-substituted phenoxy-3-hydroxy-pentanoic acid-.beta.-lactones (formula II). The .beta.-lactones are prepared by condensing relevant phenoxypropanals with dimethylketene.

Derivatives and preparation of 2,2-dimethyl-5-substituted

Growing community of inventors

Hsinchu, Taiwan

On Lee